Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Covid-19 Vaccination Rates Among Pregnant Tennessee Women by Month of Conception and Urbanization Level: March 2021 - November 2021.

Journal of Appalachian health·2026
Same author

The Impact of Artificial Intelligence on Radiology Specialty Preferences Among Canadian Medical Students and Residents.

Academic radiology·2026
Same author

Ionizing Radiation Exposure From Imaging in Pediatric Solid Organ Transplant Recipients.

Pediatric transplantation·2026
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Novel <i>DNASE2</i> Variants Linked With Neonatal Acute Liver Failure and Monogenic Systemic Lupus Erythematosus.

The Journal of rheumatology·2026
Same author

Physician-Scientist Pipeline for Pediatric Rheumatology: The Current Landscape and Future Perspectives.

Arthritis care & research·2026

Related Experiment Video

Updated: Jun 19, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Ethnic differences in pediatric systemic lupus erythematosus.

Linda T Hiraki1, Susanne M Benseler, Pascal N Tyrrell

  • 1Division of Rheumatology, Hospital for Sick Children, University of Toronto, Toronto, Canada.

The Journal of Rheumatology
|October 17, 2009
PubMed
Summary

Pediatric systemic lupus erythematosus (pSLE) is more prevalent in non-Caucasian children, who are diagnosed younger and more often develop kidney disease. However, disease activity and damage are independent of ethnicity.

Related Experiment Videos

Last Updated: Jun 19, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Genetics and Epidemiology

Background:

  • Systemic lupus erythematosus (SLE) exhibits ethnic variations in adults, but this is less understood in pediatric SLE (pSLE).
  • Understanding ethnic disparities in pSLE is crucial for equitable healthcare and targeted interventions.

Purpose of the Study:

  • To compare the prevalence and severity of major organ involvement, disease activity, and damage in pediatric SLE across different ethnic groups.
  • To investigate the impact of ethnicity on the clinical presentation and disease course of pSLE.

Main Methods:

  • An inception cohort of 265 pediatric SLE patients at Sick Kids Hospital was analyzed.
  • Patients were categorized by self-designated ethnicity and compared to the Metropolitan Toronto at-risk population.
  • Longitudinal data on organ involvement, disease activity (SLE Disease Activity Index), and damage were collected and compared among ethnic groups.

Main Results:

  • Non-Caucasian patients constituted the majority (60%) of the pSLE cohort, a higher proportion than in the general population.
  • Non-Caucasian patients were diagnosed at a younger age (12.6 years) compared to Caucasian patients (14.6 years).
  • Renal disease (nephritis) was significantly more prevalent in non-Caucasian (62%) versus Caucasian (45%) pSLE patients.

Conclusions:

  • Non-Caucasian ethnicity is linked to a higher prevalence of pediatric SLE.
  • Younger age at diagnosis and increased likelihood of nephritis are associated with non-Caucasian ethnicity in pSLE.
  • Disease activity and damage in pSLE are primarily associated with major organ involvement, irrespective of patient ethnicity.